Payment overview · 2025
General Payments
$1,639.89
86 reported records · 16 companies
Healthcare provider profile · identity verified
Steven H Lagrant, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW HARTFORD, NY · NPI 1477540789
Verified facts
What the public records show
CMS Open Payments records show Steven H Lagrant, MD received $1,639.89 in general payments during 2025 across 86 reported records.
ABBVIE INC. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $371.12 | 22.6% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $287.25 | 17.5% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.85 | 9.7% | 8 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $103.13 | 6.3% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $96.79 | 5.9% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $91.56 | 5.6% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $85.57 | 5.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.42 | 4.5% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $69.08 | 4.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62.80 | 3.8% | 3 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $53.27 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.94 | 3.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.48 | 2.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.55 | 2.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.30 | 1.9% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $29.78 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,639.89 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $263.06 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $263.06 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.51 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $126.70 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $124.28 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $103.18 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $103.13 | 6 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $96.79 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $85.97 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $85.57 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.78 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $72.53 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $69.08 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.80 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.09 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $54.91 | 3 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $53.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.71 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.16 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.85 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.48 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.55 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 154 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
154 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 517 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 108 |
| Lisinopril | Lisinopril | 358 | 101 |
| Omeprazole | Omeprazole | 340 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 313 | 104 |
| Furosemide | Furosemide | 249 | 75 |
| Losartan Potassium | Losartan Potassium | 231 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 71 |
| Simvastatin | Simvastatin | 191 | 58 |
| Metformin Hcl | Metformin Hcl | 186 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 58 |
| Metformin Hcl Er | Metformin Hcl | 164 | 45 |
| Gabapentin | Gabapentin | 159 | 50 |
| Eliquis | Apixaban | 154 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 39 |
| Allopurinol | Allopurinol | 126 | 38 |
| Alprazolam | Alprazolam | 118 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 114 | 41 |
| Xarelto | Rivaroxaban | 108 | 36 |
| Sertraline Hcl | Sertraline Hcl | 106 | 32 |
| Lorazepam | Lorazepam | 99 | 19 |
| Potassium Chloride | Potassium Chloride | 99 | 33 |
| Famotidine | Famotidine | 97 | 28 |
| Glimepiride | Glimepiride | 97 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 32 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 95 | 25 |
| Trazodone Hcl | Trazodone Hcl | 95 | 23 |
| Meloxicam | Meloxicam | 94 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 36 |
| Ozempic | Semaglutide | 83 | 20 |
| Finasteride | Finasteride | 79 | 25 |
| Ezetimibe | Ezetimibe | 75 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 21 |
| Jardiance | Empagliflozin | 73 | 23 |
| Buspirone Hcl | Buspirone Hcl | 69 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 19 |
| Celecoxib | Celecoxib | 64 | 19 |
| Carvedilol | Carvedilol | 59 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 15 |
| Clonazepam | Clonazepam | 56 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | suppressed |
| Prednisone | Prednisone | 55 | 35 |
| Ramipril | Ramipril | 55 | 21 |
| Farxiga | Dapagliflozin Propanediol | 54 | 13 |
| Torsemide | Torsemide | 51 | 18 |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Tramadol Hcl | Tramadol Hcl | 49 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 18 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Irbesartan | Irbesartan | 43 | 16 |
| Warfarin Sodium | Warfarin Sodium | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Telmisartan | Telmisartan | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | 12 |
| Glipizide | Glipizide | 38 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 37 | 12 |
| Azithromycin | Azithromycin | 36 | 29 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Klor-Con M10 | Potassium Chloride | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 17 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Desoximetasone | Desoximetasone | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Acyclovir | Acyclovir | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Victoza 3-Pak | Liraglutide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Zoloft | Sertraline Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,639.89 · 86 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, QUTENZA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error